Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO GU 2020: Updates in renal cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.20
Views: 790
Rating:

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Dr Toni Choueiri speaks to ecancer at the 2020 ASCO GU meeting in San Francisco about the latest developments in renal cancer.

Firstly he discusses a phase I/II study of a novel oral HIF-2 α inhibitor, MK-6482 which he presented at the meeting. He states that this inhibitor was well tolerated and showed promising activity in patients with advanced clear cell renal cell carcinoma. These results have also led to the development of a phase III trial.

He also mentions the possibility of combining MK-6482 with other therapies such as VEGF tyrosine kinase inhibitors and immune checkpoint inhibitors, along with the development of a biomarker to try and understand the mechanism of response and resistance.

Dr Choureri also highlights other important studies that were presented at this year's conference.

 

Related videos

follow us

WIN 2020


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation